AstraZeneca PLC (NASDAQ:AZN) Shares Sold by SeaCrest Wealth Management LLC

SeaCrest Wealth Management LLC cut its holdings in AstraZeneca PLC (NASDAQ:AZN) by 5.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 16,401 shares of the company’s stock after selling 945 shares during the period. SeaCrest Wealth Management LLC’s holdings in AstraZeneca were worth $1,075,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of AZN. Bank of Montreal Can raised its holdings in AstraZeneca by 109.6% in the 3rd quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock valued at $238,397,000 after acquiring an additional 1,605,758 shares during the last quarter. Franklin Resources Inc. raised its holdings in AstraZeneca by 8.7% in the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock valued at $1,492,649,000 after acquiring an additional 1,522,715 shares during the last quarter. Hsbc Holdings PLC raised its holdings in AstraZeneca by 750.3% in the 2nd quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock valued at $100,523,000 after acquiring an additional 1,132,362 shares during the last quarter. Farallon Capital Management LLC grew its stake in shares of AstraZeneca by 65.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock valued at $187,934,000 after buying an additional 950,000 shares during the period. Finally, Erste Asset Management GmbH purchased a new stake in shares of AstraZeneca during the 3rd quarter valued at $72,437,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Up 0.5 %

Shares of AstraZeneca stock opened at $65.68 on Thursday. The company has a fifty day moving average price of $65.98 and a 200 day moving average price of $74.69. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The stock has a market cap of $203.65 billion, a price-to-earnings ratio of 31.43, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the prior year, the company earned $0.87 EPS. The firm’s revenue was up 18.0% on a year-over-year basis. Equities research analysts forecast that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AZN has been the subject of several research reports. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.